Tag: launch

XING Mobility unveils IMMERSIO™ Matrix, an immersion-cooled marine battery system delivering twice the energy density and 3C discharge for electric vessels

New powder formula combines marine collagen, hyaluronic acid, postbiotics and selected nutrients for flexible daily beauty routinesGOTHENBURG, Sweden, June 11, 2026 /PRNewswire/ -- As beauty-from-within...

TAIPEI, June 11, 2026 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced today that the company has entered into an exclusive licensing agreement with Samil...

Strategic rollout across major e-commerce platforms in the U.S. and UK reinforces APR's expanding global beauty device footprint.Sequential launches planned across TikTok Shop and...

SINGAPORE, June 11, 2026 /PRNewswire/ -- DKSH entered a strategic distribution partnership with BridgeBio to support regulatory evaluation and potential patient access to a...

Almost half of UK consumers want a Summer Black Friday Promotion, new Independent research shows*Black Friday offers, but hotter: Joybuy's Summer Black Friday offers...

KUALA LUMPUR, Malaysia, June 11, 2026 /PRNewswire/ -- CloudMile, a leading cloud and AI company in Asia, announced on June 10 the opening of...

HONG KONG, June 11, 2026 /PRNewswire/ -- At Tencent Cloud Day Hong Kong, Tencent Cloud, the cloud business of Tencent, announced a strategic collaboration with...

MONACO, June 10, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after the project submitted its CoinGecko listing as launch preparations continue to move forward. The presale has now crossed $1.49 million in total capital raised, Stage 17 is live at $0.01877, and holder growth has passed 9,400 while AlphaSwap demo traction and audit completion continue to support the project’s pre-listing profile.

DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.

Mrs Mak and McDull Visit 24 Malls and Markets, Launching Exclusive Themed Premiums and Dining OffersThe "Hundred Flavours Survey" drew over 6,000 participants, uncovering...

NEW TAIPEI CITY, June 10, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the Phase III clinical trial...

Defiance ETFs to Launch SPCU, The 2X SpaceX ETF, as the SpaceX (SPCX) IPO Nears

Establishes a regulatory-compliant, state-of-the-art Genome-Edited (GE) Crop Field Testing Facility to accelerate global commercialization.Enables comprehensive field evaluation of a diversified crop portfolio, including drought...